Today: 9 June 2026
Palantir boosts outlook, but AI stock stays under watch
17 May 2026
2 mins read

Palantir boosts outlook, but AI stock stays under watch

New York, May 17, 2026, 16:04 EDT

  • Palantir ended Friday at $133.99, ticking up 0.19% for the day. The stock is still off about 2.8% since the May 8 close.
  • Nasdaq fell this week, breaking a six-week run, as higher oil prices and bond yields weighed on AI stocks.
  • Nvidia’s earnings set for this week are seen as the next big test for the AI trade.

Palantir Technologies stock is starting the week down from where it was before last week, after a strong sales outlook failed to resolve the bulls-versus-bears debate around one of Wall Street’s battleground AI names.

U.S. cash equities did not trade Sunday. Palantir (PLTR) ended Friday at $133.99, capping a volatile week that saw shares dip as low as $130.05 midweek. On Friday, Palantir moved between $132.29 and $135.64. Back on May 8, the stock closed higher at $137.80.

The timing is key here. U.S. stocks pulled back from their AI-driven highs on Friday as crude prices climbed and Treasury yields moved up. That can pressure growth shares—higher yields cheapen future earnings. “There’s a realization that the market had gotten way ahead of itself,” Kenny Polcari, chief market strategist at Slatestone Wealth, told Reuters. He said traders had been swept up in a “momentum AI trade.” Reuters

Palantir is facing the basic question now: can its fast revenue growth keep the stock ahead of worries about valuation? On May 4, the company said first-quarter revenue jumped 85% to $1.633 billion. U.S. revenue more than doubled to $1.282 billion, with U.S. commercial sales up 133%. Palantir bumped its 2026 revenue target to between $7.650 billion and $7.662 billion. CEO Alex Karp said, “momentum surged as we grew 85% last quarter,” and cited a Rule of 40 score of 145%. That’s a figure combining revenue growth and adjusted operating margin, which leaves out some items. SEC

Defense headlines kept moving. Ukrainian President Volodymyr Zelenskiy met with Karp last week as Kyiv widened AI use in its fight with Russia, working on a Palantir-linked project called Brave1 Dataroom that taps combat data to track and stop Russian drones. Ukraine Defence Minister Mykhailo Fedorov said “technology, AI, data analysis and the mathematics of warfare” are shaping the battlefield. Reuters also reported Palantir’s Maven AI battlefield software is poised to become a Pentagon program of record, locking in a formal long-term U.S. military deal. Reuters

Palantir shares have struggled in recent sessions, with trading turning cautious. Retail traders sold a net $82 million of Palantir stock in the week through May 13, Business Insider reported, citing JPMorgan analyst Arun Jain. They also unloaded $117 million of Microsoft and moved into semiconductor and memory names. That leaves Palantir and Microsoft grouped in the ongoing software rotation, while Nvidia is still the big AI reference point this week.

Wall Street has a divide. Bank of America stuck with its Buy and $255 target after the quarter, telling TheStreet the report was a “step-function” print. On the flip side, Jefferies analyst Brent Thill lowered his target to $70, saying the issue isn’t demand but whether growth speed can hold up. TheStreet

But risks for Palantir aren’t just about the stock. The company told investors that a lot of its customer deals run for years but can be ended with less than 12 months’ notice, and said shifts in U.S. government budgets, spending or contract timing could hit results. That’s key since government accounts for 53% of Palantir’s Q1 revenue.

Palantir’s upcoming week could depend more on outside events. Nvidia’s results come out Wednesday, with Fed minutes and new housing figures also on tap, Reuters reported. The 30-year Treasury yield is holding above 5%. If Nvidia reassures the market on AI, Palantir might see support. But if yields climb or AI stocks take another hit, recent gains after a solid quarter may not hold.

Stock Market Today

  • Regentis Biomaterials Plans European Surgeon Training for GelrinC Implant
    June 9, 2026, 9:53 AM EDT. Regentis Biomaterials' shares edged down to $1.28 ahead of the New York open as the company outlined its European launch strategy for GelrinC, a knee cartilage repair hydrogel implant. The Israeli regenerative-medicine firm will begin surgeon training in Q3 at Humanitas Research Hospital in Milan, marking a key step between CE Mark regulatory clearance and commercial use in Europe. GelrinC's "off-the-shelf" design contrasts with custom-grown products, aiming to ease adoption. However, key uncertainties remain around FDA approval in the U.S., clinical trial outcomes, market acceptance, reimbursement, and competition from established implants by Smith+Nephew and Vericel. Regentis raised $10 million at its December 2025 IPO to fund pivotal U.S. trials and PMA submission. CEO Dr. Ehud Geller called training "critical" for physician adoption ahead of broader rollout.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
ServiceNow Stock Bucks Broader Drop Ahead of Monday Test
Previous Story

ServiceNow Stock Bucks Broader Drop Ahead of Monday Test

Vale Shares Stand Out as Brazil Market Slips, Iron Ore Prices Stay Firm
Next Story

Vale Shares Stand Out as Brazil Market Slips, Iron Ore Prices Stay Firm

Go toTop